Compare MNPR & HQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MNPR | HQ |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 587.4M | 543.9M |
| IPO Year | 2019 | 2025 |
| Metric | MNPR | HQ |
|---|---|---|
| Price | $70.28 | $9.73 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 2 |
| Target Price | ★ $130.17 | $18.50 |
| AVG Volume (30 Days) | ★ 127.0K | 96.5K |
| Earning Date | 11-12-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 54.99 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $50.07 | $8.29 |
| 52 Week High | $124.82 | $45.00 |
| Indicator | MNPR | HQ |
|---|---|---|
| Relative Strength Index (RSI) | 42.77 | 34.45 |
| Support Level | $66.88 | $9.60 |
| Resistance Level | $75.33 | $13.90 |
| Average True Range (ATR) | 4.74 | 1.32 |
| MACD | 0.73 | -0.29 |
| Stochastic Oscillator | 51.81 | 3.78 |
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.
Horizon Quantum Holdings Ltd is building software infrastructure to make quantum computers accessible to commercial enterprises and hardware providers. By bridging the gap between hardware and applications, the company seeks to equip developers, researchers, and enterprises with the quantum software infrastructure needed to solve real-world problems. The company is developing tools that can automatically accelerate code written for conventional computers on quantum computers.